Phase I-II study with pixantrone, etoposide, bendamustine and rituximab in patients with relapsed aggressive B- or T-cell non-Hodgkin’s lymphoma

Project summary

If the first treatment for non-Hodgkin’s lymphoma fails, the chances of survival are drastically reduced. A new combination treatment of chemotherapy and immunotherapy may offer opportunities.

Purpose of this research
With this study, the researchers want to improve the survival rate of patients with non-Hodgkin’s lymphoma in whom previous treatment has failed.

This study is necessary because treatment options are minimal after the non-Hodgkin’s lymphoma has returned. The chance of survival is then less than a year. Therefore, an effective treatment for this group of patients is urgently needed.

The researchers think that a certain combination treatment (PREBEN) could be interesting. This consists of different medicines: chemotherapy and immunotherapy (rituximab).

Of course, such a new treatment must first be thoroughly researched before doctors can give it to patients. Important questions here are: what is a safe amount of the drug? What is an effective amount of the drug and what factors influence it?

How is this research conducted?
To conduct this study, the researchers will approach patients whose non-Hodgkin’s lymphoma has not responded to standard treatment. First, they will identify the safe dose in 24 patients. They will then measure the effect of the new combination treatment in 60 patients. For this, the researchers will, among other things, make scans at various times and collect other disease data.

Type the project impact here.